With COVID-19 a residual but still very real issue globally, Novo Holdings asked the big diagnostics question at a recent high-level roundtable: How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? The CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.

Shaped by Brexit, driven by COVID, squeezed by budgets and being engineered for the future, it seems that almost every element within UK health delivery and market access is undergoing change. How should the medtech industry prepare, and will there be implications beyond the UK?

In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues.

In the three months since Brexit, UK medtech stakeholders have seen the beginnings of new regulations, foreign trade plans being put in place, and perhaps new perceptions of medtech’s value.